The US Food and Drug Administration (FDA) has accepted for expedited review French pharma major Sanofi’s supplemental biologics license application (sBLA) for Tzield (teplizumab-mzwv) to delay the ...
The US Food and Drug Administration (FDA) has approved Rybelsus (oral semaglutide) for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, ...
This week’s Expert View comes from Albi Celaj, head of machine learning research at Deep Genomics, who reflects on how far AI-driven biology has come since its early, idealistic days. Drawing on a ...
Danish allergy immunotherapy specialist ALK Abello has announced that EURneffy 2mg nasal adrenaline spray, the UK’s first needle-free emergency anaphylaxis treatment for adults and children (≥30 kg) ...
San Diego-based Rani Therapeutics Holdings (Nasdaq: RANI), a biotherapeutics company focused on the oral delivery of biologics and drugs, has entered into a collaboration and license agreement with ...
US biotech Exelixis has announced detailed results from STELLAR-303, a global Phase III pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus regorafenib in ...
UK biotech Cyclana Bio has secured £5 million ($6.1 million) in pre-seed funding to advance its platform targeting women’s health through tissue-level therapeutics, starting with endometriosis. The ...
A future-proof pharmaceutical policy requires a healthy balance between affordability, availability, and quality. The fact that the MAUG parties, after two years of research, focus almost exclusively ...
Swedish Orphan Biovitrum, the Nordic biotech company also known as Sobi, today announced positive third-quarter 2025 financial results.
Swiss pharma giant Novartis yesterday presented positive new Pluvicto (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European ...
CNS specialist Lundbeck and fellow Denmark based Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative ...
The US Food and Drug Administration (FDA) has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback